Chen’s team found that CD2 was upregulated in breast cancer samples and that CD2 immunomodulation contributed to the mitigation of disease progression and could be used as an immunomodulatory agent in clinical treatment (15). This evidence concerns the gene CD2 and breast carcinoma.